Proteome Sciences plc

Equities

PRM

GB0003104196

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 11:35:12 2024-04-24 am EDT			5-day change	1st Jan Change
3.5 ^GBX	+7.69%		+11.46%	-22.74%

Apr. 10	Proteome Sciences shares drop as revenue plunges and swings to loss	AN
Apr. 10	Proteome Sciences plc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Proteome Sciences : AGM Statement and Result of AGM

April 25, 2017 at 10:22 am EDT

At the Company's AGM held today the Chairman, Christopher Pearce, made the following statement:

'As stated in our recent results, we expect 2017 to be a transformational year for Proteome Sciences. The combination of strong revenue growth during 2016 and operational initiatives to simplify our strategy, consolidate our resources and broaden our commercial capability, have put the Company in a good position to take advantage of the increasing opportunities afforded by quantitative proteomics. Trading remains in line with management expectations.'

All resolutions at the AGM were duly passed.

View PDF Version

« Back To News

Proteome Sciences plc published this content on 25 April 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 25 April 2017 14:22:14 UTC.

Original documenthttp://www.proteomics.com/news/post/agm-statement-and-result-of-agm-2

Public permalinkhttp://www.publicnow.com/view/2F66D7A93B50D78AC96977CB243C8EBA7D1AC3C6

Latest news about Proteome Sciences plc

Proteome Sciences shares drop as revenue plunges and swings to loss	Apr. 10	AN
Proteome Sciences plc Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 10	CI
Proteome Sciences Completes New US Lab Setup	Jan. 02	MT
Proteome Sciences Announces the Completion of Installation and Setup of Equipment in Its New US Laboratory in San Diego, California	Jan. 02	CI
Proteome Sciences says San Diego lab now fully operational	Jan. 02	AN
AIM WINNERS & LOSERS: Totally slides again; Proteome warns on earnings	Nov. 30	AN
Proteome Sciences shares drop as cuts annual revenue outlook	Nov. 30	AN
Proteome Sciences sees shares surge on SysQuant service launch	23-10-02	AN
Proteome Sciences plc Announces the Launch of Sysquant® SCP, the Commercial Service for Single Cell Proteomics Using the Power of its TMTpro? Isobaric Labelling Reagents	23-10-02	CI
FTSE 100 Finishes Flat After Choppy Week	23-08-25	DJ
UK 2063 Gilt Seen Attractively Valued Ahead of Syndicated Tap	23-08-25	DJ
FTSE 100 pushes higher ahead of Fed chair speech	23-08-25	AN
AIM WINNERS & LOSERS: Panthera Resources secures litigation financing	23-08-25	AN
Proteome Sciences shares fall as swings to interim loss on costs	23-08-25	AN
Earnings Flash (PRM.L) PROTEOME SCIENCES Posts H1 Loss GBX-0.20	23-08-25	MT
Proteome Sciences plc Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
OnTheMarket new CFO Tom Carter starts role	23-07-04	AN
Proteome Sciences repays GBP824,400 loan in full to Vulpes	23-06-01	AN
Brand Architekts CFO to Step Down in June; Successor Named	23-05-26	MT
FTSE 100 Closes Down 0.35% After Corporate Updates; Melrose Industries Shines on Guidance Lift	23-05-17	DJ
Proteome Sciences revenue up; Mpac sees improved 2023	23-05-17	AN
Proteome Sciences expanding to US with San Diego facility	23-05-12	AN
Proteome Sciences to Set Up Facility in California, US; Shares Rise 13%	23-05-12	MT
Proteome Sciences plc Expands into United States of America	23-05-12	CI
Proteome Sciences full-year revenue rises; profit multiplies	23-04-04	AN

Chart Proteome Sciences plc

Duration

Period

More charts

Company Profile

Proteome Sciences plc is a specialist provider of contract proteomics services. The services enable drug discovery, development, and biomarker identification and employ workflows for the optimum analysis of tissues, cells, and body fluids. Its principal activities involve protein biomarker research and development. It uses high-sensitivity techniques to detect and characterize differentially expressed proteins in biological samples for diagnostic, prognostic, and therapeutic applications. SysQuant and TMT MS2 are its unbiased methods for identifying and contextualizing new targets and defining mechanisms of biological activity, while analysis using super-depletion and TMTcalibrator provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. In addition, it has invented and developed the technology for TMT and TMTpro, and manufactures these small, protein-reactive chemical reagents, which are sold for multiplex quantitative proteomics.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-07-24 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
PROTEOME SCIENCES PLC	-22.74%	11.93M
ABBOTT LABORATORIES	-3.26%	187B
MEDTRONIC PLC	-2.45%	108B
BECTON, DICKINSON AND COMPANY	-4.11%	67.71B
DEXCOM, INC.	+10.55%	53.07B
CENCORA, INC.	+15.68%	47.36B
HOYA CORPORATION	+6.01%	39.73B
WEST PHARMACEUTICAL SERVICES, INC.	+10.64%	28.56B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.51%	26.55B
TERUMO CORPORATION	+15.97%	25.13B

Other Medical Equipment, Supplies & Distribution